{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:37:40Z","timestamp":1780735060764,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04328-2","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T19:35:49Z","timestamp":1751484949000},"page":"329-338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of dual-release hydrocortisone on disease control and metabolism in congenital adrenal hyperplasia: a retrospective cohort study"],"prefix":"10.1007","volume":"90","author":[{"given":"Pierluigi","family":"Mazzeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Tizianel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Sabbadin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Voltan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Ceccato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-5727","authenticated-orcid":false,"given":"Mattia","family":"Barbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"4328_CR1","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1056\/NEJMra1909786","volume":"383","author":"DP Merke","year":"2020","unstructured":"D.P. Merke, R.J. Auchus, Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N. Engl. J. Med. 383, 1248\u20131261 (2020). https:\/\/doi.org\/10.1056\/NEJMra1909786.","journal-title":"N. Engl. J. Med."},{"key":"4328_CR2","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1210\/jc.2018-01865","volume":"103","author":"PW Speiser","year":"2018","unstructured":"P.W. Speiser, W. Arlt, R.J. Auchus, L.S. Baskin, G.S. Conway, D.P. Merke et al., Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society* clinical practice guideline. J. Clin. Endocrinol. Metab. 103, 4043\u20134088 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"August","key":"4328_CR3","first-page":"1","volume":"13","author":"M Barbot","year":"2022","unstructured":"M. Barbot, P. Mazzeo, M. Lazzara, F. Ceccato, C. Scaroni, Metabolic syndrome and cardiovascular morbidity in patients with congenital adrenal hyperplasia. Front. Endocrinol. 13(August), 1\u201310 (2022).","journal-title":"Front. Endocrinol."},{"issue":"February","key":"4328_CR4","first-page":"1","volume":"11","author":"F DelleCese","year":"2021","unstructured":"F. DelleCese, A. Corsello, M. Cintoni, P. Locantore, A. Pontecorvi, S.M. Corsello et al., Switching from immediate-release to fractionated dual-release hydrocortisone may improve metabolic control and QoL in selected primary adrenal insufficiency patients. Front. Endocrinol. 11(February), 1\u20138 (2021).","journal-title":"Front. Endocrinol."},{"issue":"7","key":"4328_CR5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1530\/EC-19-0176","volume":"8","author":"V Guarnotta","year":"2019","unstructured":"V. Guarnotta, C. Di Stefano, A. Santoro, A. Ciresi, A. Coppola, C. Giordano, Dual-release hydrocortisone vs conventional glucocorticoids in adrenal insufficiency. Endocr. Connect. 8(7), 853\u2013862 (2019).","journal-title":"Endocr. Connect."},{"issue":"5","key":"4328_CR6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1530\/EJE-14-1114","volume":"172","author":"M Quinkler","year":"2015","unstructured":"M. Quinkler, R.M. Nilsen, K. Zopf, M. Ventz, M. \u00d8ksnes, Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur. J. Endocrinol. 172(5), 619\u2013626 (2015).","journal-title":"Eur. J. Endocrinol."},{"key":"4328_CR7","first-page":"3947","volume":"73","author":"M Auer","year":"2021","unstructured":"M. Auer, H. Nowotny, M. Quinkler, M. Bidlingmaier, J.M. Hawley, J. Adaway et al., Salivary steroid and 11\u2011oxygenated androgen profiles in patients with congenital adrenal hyperplasia on various glucocorticoid replacement regimens. Endocr. Abstr. 73, 3947 (2021).","journal-title":"Endocr. Abstr."},{"key":"4328_CR8","doi-asserted-by":"publisher","unstructured":"C. Simeoli, R. Ferrigno, D. Angellotti, D. Iacuaniello, C. Pivonello, M. Negri et al., SUN-358 dual release hydrocortisone as a new treatment for congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J. Endocr. Soc 3 (Suppl 1), SUN-358 (2019). https:\/\/doi.org\/10.1210\/js.2019-SUN-358.","DOI":"10.1210\/js.2019-SUN-358"},{"key":"4328_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.mce.2015.01.039","volume":"408","author":"RJ Auchus","year":"2015","unstructured":"R.J. Auchus, Molecular and Cellular Endocrinology Management considerations for the adult with congenital adrenal hyperplasia. Mol. Cell Endocrinol. 408, 190\u2013197 (2015).","journal-title":"Mol. Cell Endocrinol."},{"issue":"August 2023","key":"4328_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/cen.14967","volume":"101","author":"R Pofi","year":"2024","unstructured":"R. Pofi, N.P. Krone, J.W. Tomlinson, Long - term health consequences of congenital adrenal hyperplasia. Clin. Endocrinol. 101(August 2023), 318\u2013331 (2024).","journal-title":"Clin. Endocrinol."},{"issue":"5","key":"4328_CR11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.bbadis.2011.02.003","volume":"1812","author":"S Chung","year":"2011","unstructured":"S. Chung, G.H. Son, K. Kim, Circadian rhythm of adrenal glucocorticoid: Its regulation and clinical implications. BiochimBiophys Acta - Mol. Basis Dis. 1812(5), 581\u2013591 (2011). https:\/\/doi.org\/10.1016\/j.bbadis.2011.02.003.","journal-title":"BiochimBiophys Acta - Mol. Basis Dis."},{"issue":"12","key":"4328_CR12","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1210\/jc.2012-2102","volume":"97","author":"GP Finkielstain","year":"2012","unstructured":"G.P. Finkielstain, M.S. Kim, N. Sinaii, M. Nishitani, C. Van Ryzin, S.C. Hill et al., Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 97(12), 4429\u20134438 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"4328_CR13","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1210\/jc.2010-0917","volume":"95","author":"W Arlt","year":"2010","unstructured":"W. Arlt, D.S. Willis, S.H. Wild, N. Krone, E.J. Doherty, S. Hahner et al., Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J. Clin. Endocrinol. Metab. 95(11), 5110\u20135121 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"November 2019","key":"4328_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2019.105540","volume":"197","author":"L Paizoni","year":"2020","unstructured":"L. Paizoni, M.K. Auer, H. Schmidt, A. H\u00fcbner, M. Bidlingmaier, N. Reisch, Effect of androgen excess and glucocorticoid exposure on metabolic risk profiles in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J. Steroid Biochem. Mol. Biol. 197(November 2019), 105540 (2020).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"1","key":"4328_CR15","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1542\/peds.2005-1005","volume":"117","author":"TMK V\u00f6lkl","year":"2006","unstructured":"T.M.K. V\u00f6lkl, D. Simm, C. Beier, H.G. D\u00f6rr, Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 117(1), e98\u2013e105 (2006).","journal-title":"Pediatrics"},{"issue":"3","key":"4328_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/MED.0000000000000545","volume":"27","author":"LG Gomes","year":"2020","unstructured":"L.G. Gomes, B.B. Mendonca, T.A.S.S. Bachega, Long-term cardio-metabolic outcomes in patients with classical congenital adrenal hyperplasia: Is the risk real?. CurrOpin Endocrinol. Diabetes Obes. 27(3), 155\u2013161 (2020).","journal-title":"CurrOpin Endocrinol. Diabetes Obes."},{"issue":"9","key":"4328_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1371\/journal.pone.0024204","volume":"6","author":"CF Mooij","year":"2011","unstructured":"C.F. Mooij, J.M. Kroese, F.C.G.J. Sweep, A.R.M.M. Hermus, C.J. Tack, Adult patients with congenital adrenal hyperplasia have elevated blood pressure but otherwise a normal cardiovascular risk profile. PLoS One 6(9), 2\u20136 (2011).","journal-title":"PLoS One"},{"issue":"6","key":"4328_CR18","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1210\/js.2019-00136","volume":"3","author":"E Whittle","year":"2019","unstructured":"E. Whittle, H. Falhammar, Glucocorticoid regimens in the treatment of congenital adrenal hyperplasia: a systematic review and Meta-Analysis. J. Endocr. Soc. 3(6), 1227\u20131245 (2019).","journal-title":"J. Endocr. Soc."},{"issue":"1","key":"4328_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13633-016-0035-5","volume":"2016","author":"TD Nebesio","year":"2016","unstructured":"T.D. Nebesio, J.L. Renbarger, Z.M. Nabhan, S.E. Ross, J.E. Slaven, L. Li et al., Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia. Int. J. Pediatr. Endocrinol. 2016(1), 1\u20139 (2016).","journal-title":"Int. J. Pediatr. Endocrinol."},{"issue":"2","key":"4328_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1530\/EJE-10-0877","volume":"164","author":"H Falhammar","year":"2011","unstructured":"H. Falhammar, H.F. Nystr\u00f6m, A. Wedell, M. Thor\u00e9n, Cardiovascular risk, metabolic profile, and body composition in adult males with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur. J. Endocrinol. 164(2), 285\u2013293 (2011).","journal-title":"Eur. J. Endocrinol."},{"key":"4328_CR21","first-page":"123","volume":"60","author":"V Guarnotta","year":"2021","unstructured":"V. Guarnotta, R. Amodei, C. Giordano, ScienceDirect Pharmacology Metabolic comorbidities of adrenal insufficiency: focus on steroid replacement therapy and chronopharmacology. CurrOpinPharmacol 60, 123\u2013132 (2021).","journal-title":"CurrOpinPharmacol"},{"issue":"9","key":"4328_CR22","first-page":"3082","volume":"84","author":"L Plat","year":"1999","unstructured":"L. Plat, R. Leproult, M.L. Hermite-baleriaux, F. Fery, J. Mockel, K.S. Polonsky, Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning *. J. Clin. Endocrinol. Metab. 84(9), 3082\u20133092 (1999).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"4328_CR23","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1210\/jcem-48-5-760","volume":"48","author":"RM Boyar","year":"1979","unstructured":"R.M. Boyar, M. Witkin, A. Carruth, J. Ramsey, Circadian cortisol secretory rhythms in cushing\u2019s disease. J. Clin. Endocrinol. Metab. 48(5), 760\u2013765 (1979).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"4328_CR24","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1210\/jc.2008-2380","volume":"94","author":"M Debono","year":"2009","unstructured":"M. Debono, C. Ghobadi, A. Rostami-Hodjegan, H. Huatan, M.J. Campbell, J. Newell-Price et al., Modified-release hydrocortisone to provide circadian cortisol profiles. J. Clin. Endocrinol. Metab. 94(5), 1548\u20131554 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"4328_CR25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/ejendo\/lvae107","volume":"191","author":"V Guarnotta","year":"2024","unstructured":"V. Guarnotta, C. Di Stefano, L. Tomasello, G. Pizzolanti, G. Arnaldi, C. Giordano et al., Conventional steroids vs. dual-release hydrocortisone on metabolic, cardiovascular, and bone outcomes in adrenal insufficiency: a 10-year study. Eur. J. Endocrinol. 191(3), 300\u2013311 (2024).","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"4328_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1530\/EJE-09-0170","volume":"161","author":"G Johannsson","year":"2009","unstructured":"G. Johannsson, R. Bergthorsdottir, A.G. Nilsson, H. Lennernas, T. Hedner, S. Skrtic, Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur. J. Endocrinol. 161(1), 119\u2013130 (2009).","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"4328_CR27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s12020-015-0681-z","volume":"51","author":"R Giordano","year":"2016","unstructured":"R. Giordano, F. Guaraldi, E. Marinazzo, F. Fumarola, A. Rampino, R. Berardelli et al., Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison\u2019s disease. Endocrine 51(2), 360\u2013368 (2016).","journal-title":"Endocrine"},{"issue":"3","key":"4328_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S2213-8587(17)30398-4","volume":"6","author":"AM Isidori","year":"2018","unstructured":"A.M. Isidori, M.A. Venneri, C. Graziadio, C. Simeoli, D. Fiore, V. Hasenmajer et al., Articles Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. LANCET Diabetes Endocrinol. 6(3), 173\u2013185 (2018).","journal-title":"LANCET Diabetes Endocrinol."},{"key":"4328_CR29","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT03760835?tab=history&a=1 (Last Access 27th May 2025)."},{"key":"4328_CR30","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1530\/EC-18-0257","volume":"7","author":"F Ceccato","year":"2018","unstructured":"F. Ceccato, F. Ceccato, E. Selmin, C. Sabbadin, M.D. Costa, G. Antonelli et al., Improved salivary cortisol rhythm with dual-release hydrocortisone. Endocr. Connect. 7, 965\u2013974 (2018).","journal-title":"Endocr. Connect."},{"issue":"February","key":"4328_CR31","first-page":"473","volume":"97","author":"B Ekman","year":"2012","unstructured":"B. Ekman, B.E. Engstro, T. Olsson, O. Ragnarsson, M. Ryberg, J. Wahlberg, Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J. Clin. Endocrinol. Metab. 97(February), 473\u2013481 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4328_CR32","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1007\/s12020-024-03711-9","volume":"84","author":"NT J\u00f8rgensen","year":"2024","unstructured":"N.T. J\u00f8rgensen, V. Brun, B. Stina, W. Borresen, T. Christoffersen, N.R. J\u00f8rgensen et al., Dual-release hydrocortisone improves body composition and the glucometabolic profile in patients with secondary adrenal insufficiency. Endocrine 84, 1182\u20131192 (2024).","journal-title":"Endocrine"},{"issue":"4","key":"4328_CR33","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000500071","volume":"74","author":"Y Serin","year":"2019","unstructured":"Y. Serin, N. Acar, Effect of circadian rhythm on metabolic processes and the regulation of energy balance. Ann. Nutr. Metab. 74(4), 322\u2013330 (2019).","journal-title":"Ann. Nutr. Metab."},{"key":"4328_CR34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1530\/EJE-17-0067","volume":"176","author":"AG Nilsson","year":"2017","unstructured":"A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlqvist, B. Ekman, Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study. Eur. J. Endocrinol. 176, 715\u2013725 (2017).","journal-title":"Eur. J. Endocrinol."},{"key":"4328_CR35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1530\/EC-17-0368","volume":"7","author":"LM Mongio\u00ec","year":"2018","unstructured":"L.M. Mongio\u00ec, Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life. Endocr. Connect. 7, 211\u2013219 (2018).","journal-title":"Endocr. Connect."},{"issue":"3","key":"4328_CR36","first-page":"587","volume":"46","author":"VGJ Giannelli","year":"2023","unstructured":"V.G.J. Giannelli, L.C.E. Arvat, E.G.S. Grottoli, M.M.R. Giordano, Benefits of dual \u2011 release hydrocortisone treatment on central adiposity and health \u2011 related quality of life in secondary adrenal insufficiency. J. Endocrinol. Invest. 46(3), 587\u2013597 (2023).","journal-title":"J. Endocrinol. Invest."},{"issue":"5","key":"4328_CR37","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1530\/EJE-08-0874","volume":"160","author":"M Debono","year":"2009","unstructured":"M. Debono, R.J. Ross, J. Newell-Price, Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur. J. Endocrinol. 160(5), 719\u2013729 (2009).","journal-title":"Eur. J. Endocrinol."},{"issue":"6","key":"4328_CR38","first-page":"1797","volume":"102","author":"CM Jones","year":"2017","unstructured":"C.M. Jones, A. Mallappa, N. Reisch, N. Nikolaou, N. Krone, B.A. Hughes et al., Modified-release and conventional glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 102(6), 1797\u20131806 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"4328_CR39","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1530\/EJE-15-0064","volume":"173","author":"M Debono","year":"2015","unstructured":"M. Debono, A. Mallappa, V. Gounden, A.A. Nella, R.F. Harrison, C.A. Crutchfield, P.S. Backlund, S.J. Soldin, R.J. Ross, D.P. Merke, Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers. Eur. J. Endocrinol. 173(6), 727\u2013737 (2015). https:\/\/doi.org\/10.1530\/EJE-15-0064.","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"4328_CR40","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1210\/clinem\/dgab051","volume":"106","author":"A Brac","year":"2021","unstructured":"A. Brac, D. Perriere, A.L. Hirschberg, A. Juul, J. Newell-price, C.G. Perry et al., Modified-release hydrocortisone in congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 106(5), 2063\u20132077 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"March","key":"4328_CR41","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1210\/jc.2014-3809","volume":"100","author":"A Mallappa","year":"2015","unstructured":"A. Mallappa, N. Sinaii, P. Kumar, M.J. Whitaker, L. Daley, D. Digweed et al., A phase 2 study of Chronocort, a modified-release adults with classic congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 100(March), 1137\u20131145 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"4328_CR42","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1210\/jc.2013-1381","volume":"98","author":"F Fanelli","year":"2013","unstructured":"F. Fanelli, A. Gambineri, I. Belluomo, A. Repaci, V.D. Di Lallo, G. Di Dalmazi et al., Androgen profiling by liquid chromatography-tandem mass spectrometry (LC-MS\/MS) in healthy normal-weight ovulatory and anovulatory late adolescent and young women. J. Clin. Endocrinol. Metab. 98(7), 3058\u20133067 (2013).","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04328-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04328-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04328-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:00:32Z","timestamp":1758772832000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04328-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["4328"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04328-2","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"1 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Area Centro-Est Veneto (Date 19-Dec-2024\/AOP3569).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}